Streetbeat News

TSHA

Taysha Gene Therapies, Inc.

https://www.tayshagtx.com

Industry

Biotechnology

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Open

2.22

Mkt cap

434M

Volume

5.6M

High

2.28

P/E Ratio

3.37

52-wk high

4.32

Low

2.06

Div yield

N/A

52-wk low

1.19

Taysha Gene Therapies has regained compliance with Nasdaq, as per a written notice received from the exchange. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 5:20 pm

The article lists the stocks that gained and lost in Tuesday's mid-day session. Notable gainers include Axcella Health, Tivic Health Systems, iCoreConnect, LifeVantage Corporation, and EBET, among others. On the other hand, Antelope Enterprise Holdings, Genius Group, BioNexus Gene Lab, T2 Biosystems, and ReTo Eco-Solutions were among the losers. NIO Inc. also fell by 7.5% after reporting worse-than-expected Q2 financial results and issuing Q3 guidance.

Portfolio Pulse from Lisa Levin

August 29, 2023 | 4:51 pm

Several US stocks traded higher on Tuesday, with iCoreConnect Inc., Big Lots, Inc., Globalstar, Inc., UP Fintech Holding Limited, PDD Holdings Inc., Goosehead Insurance, Inc, Taysha Gene Therapies, Inc., Ginkgo Bioworks Holdings, Inc., Inhibrx, Inc., KE Holdings Inc., Gravity Co., Ltd., NovoCure Limited, Aclaris Therapeutics, Inc., Jackson Financial Inc., Chico's FAS, Inc., Futu Holdings Limited, Opera Limited, BeiGene, Ltd., and AlloVir, Inc. all recording significant gains. The increases were driven by a variety of factors, including better-than-expected quarterly results, new CEO appointments, licensing agreements, and strategic partnerships.

Portfolio Pulse from Lisa Levin

August 29, 2023 | 2:33 pm

Taysha Gene Therapies has received a written notice from Nasdaq stating that the company has regained compliance. This information was disclosed in an 8K filing.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 11:18 am

Several US stocks recorded losses in Monday's pre-market trading session. These include Better Home & Finance Holding Company (BETR), which dipped 15.1% following its business combination with Aurora Acquisition. Ideanomics (IDEX) tumbled 8.8% after reporting Q2 results. Scilex Holding Company (SCLX) declined 4.3% after a 4% fall on Friday. Domo (DOMO) fell 4.2% after issuing a below-consensus Q3 outlook and lowering FY24 guidance. Beneficient (BENF) fell 3.3% after a 15% jump on Friday due to the completion of System and Organization Controls certifications. Taysha Gene Therapies (TSHA) fell 3.2% after a 5% decline on Friday following the FDA's Fast Track Designation to TSHA-102.

Portfolio Pulse from Lisa Levin

August 28, 2023 | 9:43 am

During Thursday's pre-market session, several healthcare stocks experienced significant movements. CollPlant Biotechnologies, China SXT Pharmaceuticals, Taysha Gene Therapies, NeuBase Therapeutics, Nemaura Medical, and Aytu BioPharma saw increases in their shares, while Societal CDMO, Kiora Pharmaceuticals, OKYO Pharma, Meihua Intl Medical Techs, Avalo Therapeutics, and Vincerx Pharma experienced decreases.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 1:06 pm

NVIDIA, Guess?, and Taysha Gene Therapies shares are trading higher. NVIDIA reported better-than-expected Q2 results, issued Q3 revenue guidance above estimates, and approved an additional $25 billion in share repurchases. Guess? also reported better-than-expected Q2 results and issued FY24 EPS guidance above estimates. Taysha Gene Therapies received Fast Track Designation from the U.S. FDA for TSHA-102 in Rett Syndrome.

Portfolio Pulse from ryanfaloona@benzinga.com

August 24, 2023 | 12:25 pm

Taysha Gene Therapies has been granted Fast Track Designation by the U.S. FDA for TSHA-102 in Rett Syndrome. This designation is meant to speed up the development and review of therapies that could address unmet medical needs for serious or life-threatening conditions. TSHA-102 has also received Orphan Drug and Rare Pediatric Disease designations from the FDA and the European Commission.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 12:03 pm

GordonMD® Global Investments LP has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (NASDAQ:TSHA). The funds will be used to fund clinical development of TSHA-102 in Rett syndrome and support program activities for TSHA-120 in giant axonal neuropathy (GAN).

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 3:30 pm

Insiders at Taysha Gene Therapies, Amarin Corporation, Rapid Micro Biosystems, and Indaptus Therapeutics have recently made significant purchases of their companies' stocks. Taysha Gene Therapies reported initial clinical data from the first adult Rett Syndrome patient dosed in the REVEAL Phase 1/2 trial and announced $150 million private placement financing. Amarin posted a profit for the second quarter. Rapid Micro Biosystems and Indaptus Therapeutics posted narrower-than-expected quarterly losses.

Portfolio Pulse from Lisa Levin

August 17, 2023 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.